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Abstract:
Introduction: Expression of human telomerase reverse transcriptase (hTERT) occurs in most cancers but its relation with obesity is 
unclear. This study explores the association between leptin levels and anthropometric indices with hTERT mRNA levels in breast cancer 
patients of different obesity grades.
Materials and methods: In this case-control study, 65 breast cancer patients participated. Expression of tissues hTERT mRNA was 
carried out by real-time reverse transcription polymerase chain reaction. Leptin concentrations were measured by enzyme-linked 
immunoassay.
Results: Twelve patients (18.46%) were hTERT negative and 53(81.54%) were positive. hTERT mRNA levels were associated with 
BMI but not with waist circumference (WC) (r = 0.219, P = 0.22) and waist to hip ratio (WHR) (r = 0.212, P = 0.237). Leptin level and 
hTERT mRNA levels (r = 0.484, P = 0.008) were correlated as well as BMI and hTERT expression.
Conclusions: This study has shown a correlation between leptin levels and hTERT expression. These findings may clarify the role of 
leptin in breast carcinogenesis, and hence obesity could be responsible for increased incidences in breast cancer as well as its progression 
via enhanced production of leptin.
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Introduction
Breast cancer is the most common cancer for women 
with more than one million new cases detected each 
year.1–3 Accumulating  data  suggest  that  lifestyle  is 
implicated  in  the  development  of  breast  cancer.4 
In  women  with  invasive  breast  cancer,  a  direct 
relation between high BMI (.25) and large tumor 
size and axillaries lymph node involvement (ALNI) 
has been reported.5 It has also been shown that obesity 
in postmenopausal women is considered a risk factor 
for the progression of breast cancer.6 Obesity is also 
associated with an increased mortality rate in women 
diagnosed with breast cancer.7,8
The exact molecular link(s) between obesity and 
breast  cancer  are  not  fully  understood.  However, 
adipokines  are  considered  responsible  for  this 
connection. Leptin is an adipocyte derived hormone 
and  obesity  is  associated  with  high  circulating 
plasma  levels  of  leptin.9  It  has  been  shown  that 
leptin  stimulates  proliferation  of  various  types  of 
pre-neoplastic  and  neoplastic  cells.10  Leptin  also 
acts as an inflammatory cytokine and by triggering 
interleukin-6 and other cytokines release, influences 
immune system function.10
Numerous studies have demonstrated that telom-
erase is activated in the vast majority of cancer types, 
including breast cancers. Telomerase activity has been 
detected in 80%–95% of breast tumor samples by the 
Telomeric  Repeat Amplification  Protocol  assay,11–13 
and its up-regulation is observed as an early event 
during progression to malignancy of breast tumor.14 
Some other studies have shown conflicting results for 
traditional  prognostic  indicators,  disease  outcome, 
and telomerase activity with clinical and pathological 
parameters.15–17 Zarghami et al have demonstrated that 
the difference in relative telomerase activity (RTA) 
between stages and grades is strong and statistically 
significant.18  This  suggests  that  telomerase  activity 
may be influenced by parameters other than clinical/
pathological features alone, such as telomerase inhibi-
tors, tissue viability, and obesity status. It has been 
shown that enhanced expression of human telomerase 
reverse transcriptase (hTERT), the catalytic subunit of 
telomerase, is a direct determinant of telomerase activ-
ity in cancers.19 Nonetheless, the relationship between 
telomerase and obesity in breast cancer is unclear.
Therefore,  the  objectives  of  this  study  were  to 
evaluate hTERT mRNA expression in human breast 
cancer patients with different grades of obesity and 
to assess the relationship between mRNA levels of 
hTERT and clinicopathological variables, anthropo-
metric indices and leptin as an adipocytokine.
Methods
Chemical compounds
Enzymes, molecular biology reagents, kits, and chemical 
reagents were obtained from the following sources: 
Tris-HCl,  MgCl2,  (Fisher  Scientific,  Pittsburg,  PA); 
RNase inhibitors (Promega, Madison, WI); PCR buffer, 
Taq HotStar polymerase (Qiagen, Hilden, Germany), 
RNX plus reagent (Cinnagene, Iran), DNase I RNase-
free  (Fermentas,  USA),  RevertAidTM  First  cDNA 
synthesis kit (Fermentas, USA), chloroform, ethanol, 
and  isopropanol  (Merck,    Germany),  Syber  Green  I 
master mix (Fermentas, USA).
Subject
This case–control study was conducted from September   
2009 to March 2010. The study involved 65 women 
diagnosed with breast cancer attending the Department 
of Sur  gery and Health examination clinics at Imam 
Reza Hospital, Tabriz, Iran. Patients confirmed in term 
of histopathological stages and grades were included 
in the study. Histopathological information revealed 
that there were 46 cases of invasive ductal carcinoma, 
7 cases of invasive lobular carcinoma, and 12 cases of 
carcinoma in situ.
Body mass index (BMi)
According to the WHO Report 2000,20 BMI was calcu-
lated as kg/m2 using information from clinical notes at 
time of diagnosis. The subjects were divided into four 
categories (underweight with BMI , 18.5 kg/m2, normal 
weight with 18.5–24.99 kg/m2, overweight with BMI 
24.9–29.99 kg/m2 and obese with BMI . 29.99 kg/m2).
Questionnaire collection
Written informed consent was obtained from all subjects 
after  confirmation  of  their  inclusion  in  the  study. 
All  participants  filled  out  a  questionnaire  covering 
information  on  social  demographic  characteristics, 
menstrual and reproductive history, body mass index, 
fat  distribution,  age,  menopausal  status,  lifestyle 
behaviours,  education  status  and  medical  history. 
Data collectors were unaware of the study hypothesis. 
Data  on  height,  weight,  and  circumferences  of  the Leptin and hTeRT expression in breast cancer
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waist and hip by using standardized techniques were 
collected. BMI, subject’s weight in kilograms divided 
by the square of their height in meters, was used as 
an indicator of generalized obesity. In addition, waist 
circumference (WC) and waist-to-hip ratio (WHR) rep-
resent an anthropometric measure of central adiposity. 
The  influence  of  treatment  on  measurements  was 
reduced by getting questionnaire data prior to surgery.
Sample preparation
Immediately after the interview, a 10 ml blood sam-
ple was drawn into coded EDTA-treated tubes. The 
sample was centrifuged at 3000 rpm for 10 minutes 
at  room  temperature  within  1  hour  of  collection. 
Plasma, Buffy coat and red blood cells were sepa-
rated and stored at −70 °C until subsequent analysis. 
In addition, during surgery tumor tissue samples were 
taken into liquid nitrogen in sterile tubes, then imme-
diately aliquoted and stored at −70 °C until subse-
quent analysis. To avoid the influence of treatment on 
measurements, questionnaire data, blood specimens 
and tumor tissue samples were obtained prior to ini-
tiation of breast cancer surgery.
Preparation of total RnA
Approximately 100 mg of tissue was quickly frozen in 
liquid nitrogen. The sample was transferred to the labo-
ratory and was manually pulverized with a hammer to a 
fine powder. The powder was collected and suspended 
in 1 ml of RNX plus reagent in a clean RNase-free tube 
and was incubated for 5 minutes at room temperature. 
After incubation, 200 µl chloroform was added, shaken 
rigorously for 15 seconds, and incubated for another 
5 minutes. The mixture was centrifuged at 12000 g for 
15 minutes. The aqueous phase was transferred to a 
clean RNase-free tube. The total RNA was precipitated 
by adding 0.5 ml isopropyl alcohol and incubating for 
15 minutes at room temperature. The pellet includ-
ing total RNA was washed using 75% ethanol and 
  centrifuged at 7500 g for 8 minutes. After drying the 
ethanol, the RNA pellet was dissolved in TE buffer. 
The concentration and quantity of total RNA was cal-
culated based on OD260/280 ratio measurements and 
agarose gel electrophoresis, respectively.
cDnA synthesis
RNA  was  converted  to  cDNA  after  treating  with 
DNase I. Reverse transcription of RNA was performed 
in a final volume of 20 µl containing cDNA first strand 
synthesis buffer (Fermentas, USA) random hexamer 
primers and 1 µg of total RNA. According to manu-
facturer protocol, the samples were sequentially incu-
bated at 65 °C for 10 min and 42 °C for 60 min. Reverse 
transcriptase was inactivated by heating at 70 °C for 
5 min followed by cooling at 4 °C for 5 min.
Quantitative Real-Time Reverse 
Transcription polymerase chain 
Reaction (qRT-pcR)
The cDNA samples served as template in real-time 
PCR. The beta-actin cDNA served as internal control 
for quantitation. After quantitation, results were ana-
lyzed by 2–∆∆Ct method.
Measurement of hTeRT mRnA
Levels of hTERT RNA molecules were determined 
by quantitative real-time RT-PCR technique using the 
Syber Green-I (Roche, Germany) by the Rotor-GeneTM 
6000 system (Corbett Research, Australia) according 
to the manufacturer’s instructions. After cDNA syn-
thesis, specific primers were used to amplify hTERT 
mRNA  (Table  1).  Alternative  spliced  variants  of 
hTERT mRNA were not measured because they do 
not reconstitute telomerase activity.21,22 The quality of 
real-time PCR reactions was controlled by running 
standard samples as duplicate. 5-fold serial dilutions 
of  cDNA  obtained  from  the  T47D  breast  cell  line 
Table 1. Sequences of primers for RT-PCR.
Genes and oligonucleotide Location sequence pcR product size (pb)
hTeRT
  Forward primer 2165F 5′CCgCCTgAgCTgTACTTTgT3′ 198
  Reverse primer 2362R 5′CAggTgAgCCACgAACTgT3′
Beta-actin
  Forward primer 787F 5′TCCCTggAgAAgAgCTACg3′ 131
  Reverse primer 917R 5′gTAgTTTCgTggATgCCACA3′Rahmati-Yamchi et al
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served as samples with strong expression of hTERT 
gene (Fig. 1). The beta-actin mRNA was measured as 
the internal control by specific primers (Table 1). The 
program for real-time PCR reaction was as follows: 
initial denaturation at 95 °C for 10 minutes, followed 
by 40 cycles of denaturation at 95 °C for 15 seconds, 
annealing at 60 °C for 30 seconds and extension at 
72 °C for 30 seconds. Finally, amplicons were assessed 
by melting curve analysis of 70 °C to 95 °C.
Measurement of plasma Leptin Level
Plasma leptin concentration was determined with the 
use of commercially available quantitative sandwich 
enzyme-linked immunosorbent assay (ELISA) with a 
detection limit of 0.2 ng/ml (mediagnost Leptin-ELISA 
E07,  Germany).  Masked  split  specimens  included 
within each batch were used to calculate the coefficient 
of  variation  (CV)  within  and  between  batches:  the 
intra- and inter-assay CVs of leptin were below 10% 
for both. All matched blood samples were handled 
identically  and  assayed  in  the  same  analytical  run. 
The blood samples were labeled by number only and 
ordered randomly within each case–control pair.
statistical Analysis
Differences between obese, overweight and   non-obese 
groups in age at enrollment, age at menarche, age at 
menopause,  and  parity  numbers  were  tested  using 
the Student’s t-test. In addition, the chi-square test 
was used to evaluate differences in categorical breast 
cancer risk factors between obese, overweight and 
non-obese. Linear regressions were used to examine 
relationships between hTERT expression and anthro-
pometric  measures  of  adiposity  among  subjects. 
All  statistical  analysis  was  conducted  using  SPSS 
statistical  software  (version  16).  P  values  below 
the  0.05  (P  ,  0.05)  were  considered  statistically 
significant.
Results
Descriptive data for three groups (obese, overweight 
and  non-obese)  of  patients  at  baseline  are  summa-
rized in Table 2. The mean age (±SD) of obese, over-
weight  and  non-obese  subjects  were  43.41  ±  9.1, 
47.88 ± 11.2 and 44.06 ± 10.17 years, respectively. 
There  were  no  statistically  significant  differences 
between non-obese as control, overweight and obese 
cases in terms of age at marriage (20.91 ± 1.3 vs. 
20.93  ±  2.8  and  17.47  ±  1.6  years,  respectively), 
age at menarche (13.38 ± 0.184 vs. 13.5 ± 0.282 and 
13.41 ± 0.309 years, respectively), menopausal status 
(33  premenopause  vs.  32  postmenopause  patients) 
and age at menopause (49 ± 0.9 vs. 48.3 ± 0.76 and 
48.6 ± 0.83 years),   family history of obesity, stress, 
blood pressure, university education and active cig-
arette  consumption.  By  contrast,  it  was  found  that 
the  family  history  of  breast  cancer  was  higher  in 
non-obese  patients  (61.7%  vs.  13.3%  and  18.75%, 
  respectively).  There  were  statistically  significant 
differences  between  three  groups  for  anthropomet-
ric measures of adiposity and BMI (23.12 ± 1.3 vs. 
27.34 ± 1.7 and 31.92 ± 2 kg/m2). The average WC 
was significantly lower in non-obese and overweight 
than  obese  breast  cancer  patients  (85.85  ±  8.3  vs. 
87.76 ± 9.7 and 94.41 ± 5.5 cm, P , 0.05); but the aver-
age WHR was not statistically significant (0.84 ± 0.07 
vs. 84 ± 0.11 and 0.86 ± 0.05, P , 0.05, respectively). 
As shown in Figure 2, there was a weak relationship 
between hTERT mRNA levels and BMI. The average 
hTERT mRNA level in non-obese group was 2.32, in 
overweight group was 2.65 and in obese group was 
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Figure 1. A) hTeRT standard curve (R2 = 0.99, M = −3.4, e = 0.96) 
and B) Beta actin standard curve (R2 = 0.99, M = −3.46, e = 0.94), 
  concentration unit in x-axis is nanogram per reaction.Leptin and hTeRT expression in breast cancer
Breast Cancer: Basic and Clinical Research 2011:5  31
Table 2. Characteristics of obese and non-obese breast cancer patients with reference to BMi.
Baseline characteristics normal (n = 34) 
Mean ± sD
Overweight (n = 15) 
Mean ± sD
Obese (n = 16) 
Mean ± sD
P value
Age at enrollment (yrs) 44.06 ± 10.17 47.88 ± 11.2 43.41 ± 9.1 0.351
Age at menarche (yrs) 13.38 ± 0.184 13.5 ± 0.282 13.41 ± 0.309 0.982
Age at marriage (yrs) 20.91 ± 1.3 20.93 ± 2.8 17.47 ± 1.6 0.291
Age at menopause (yrs) 49 ± 0.91 48.3 ± 0.76 48.6 ± 0.83 0.781
height (cm) 163.08 ± 6.9 161.5 ± 5.8 157.6 ± 3.4 0.019
Weight (kg) 61.4 ± 5.3 71.66 ± 6.3 79.11 ± 5.4 0.01
BMi (kg/m2) 23.12 ± 1.3 27.34 ± 1.7 31.92 ± 2 0.000
WC (cm) 85.85 ± 8.3 87.76 ± 9.7 94.41 ± 5.5 0.002
hC (cm) 101.5 ± 8.1 105.4 ± 4.3 109.1 ± 4.8 0.001
WhR 0.84 ± 0.07 0.84 ± 0.11 0.86 ± 0.05 0.767
Body fat % 34.2 ± 6 37.23 ± 4.6 42.82 ± 3.8 0.009
normal (n = 34) 
no. (%)
Overweight (n = 15) 
no. (%)
Obese (n = 16) 
no. (%)
P value
Family history of  Yes 21 (61.7) 2 (13.3) 3 (18.75) 0.003
breast cancer  no 13 (38.3) 13 (86.7) 13 (81.25)
Family history of obesity  Yes 24 (70.59) 10 (66.6) 15 (93.75) 0.09
  no 10 (29.41) 5 (33.4) 1 (6.25)
Stress  Yes 33 (50.77) 16 (24.61) 17 (26.15) 0.61
  no 1 (50) 1 (50) 0 (0)
Blood pressure  Yes 9 (47.4) 5 (26.3) 5 (26.3) 0.97
  no 25 (51) 12 (24.48) 12 (24.48)
University education  Yes 28 (47.4) 15 (25.4) 17 (27.1) 0.11
  no 6 (66.6) 3 933.3) 0 (0)
Active cigarette  Yes 1 (33.3) 2 (66.6) 0 (0) 0.22
  no 33 (50) 15 (22.7) 17 (27.8)
Menopause status  Premenopausal 19 (57.57) 5 (15.15) 9 (27.27) 0.09
  Postmenopausal 15 (46.87) 10 (31.25) 7 (21.87)
2.98 nanogram. In contrast, any direct contribution of 
abdominal obesity on hTERT gene expression was not 
found (Fig. 3).
hTeRT mRnA Levels in Breast  
Tumor Tissues
Twelve (18.46%) samples were scored hTERT nega-
tive (hTERT Ct . 35) whilst 53 (81.54%) samples 
scored hTERT positive (hTERT Ct # 35) as deter-
mined by 2–∆∆Ct value (Fig. 4). In this run, three normal 
breast tissues are tested as hTERT negative sample 
and  they  did  not  amplified. Among  these  hTERT-
positive tumors, the differences of 2–∆∆Ct values were 
observed  ranging  from  1.0  to  17.  Figure  5  shows 
hTERT mRNA levels in breast tumor tissues by a 
real-time qRT-PCR assay was developed on human 
breast tissues. hTERT mRNA was express in relative 
unites after normalized to beta actin mRNA by using 
of q-gene software.
correlation Between hTeRT mRnA 
Levels and clinical staging  
and pathological Grading
Data analysis for assessing any possible correlation 
between  expression  of  hTERT  mRNA  and  tumor 
staging and grading in all patients showed that most 
positive samples were in stage II and III and grade 1 
and 2 (Table 3). There was a significant difference 
between obese and non-obese patients in stage III and 
grade 2 in terms of hTERT mRNA presence.
Association Between plasma  
Leptin Levels and Tumor Tissue  
hTeRT mRnA Levels
Data  analysis  revealed  a  significant  direct  correla-
tion between levels of plasma leptin and levels of 
hTERT mRNA in breast tumor tissue in the subjects 
(r = 0.484, P = 0.008) (Fig. 6).Rahmati-Yamchi et al
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Discussion
Obesity or Adiposity is one of the major risk factors 
for development and progression of breast cancer in 
the postmenopausal women.23 It seems that the pos-
sible biological mechanism which causes excess adi-
posity and breast cancer risk is that adiposity increases 
circulating  levels  of  estrogens  through  peripheral 
conversion of androgens to estrogens by aromatase 
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Figure 3. Correlation between hTeRT gene expression with WC and 
WhR in A) obese and B) non-obese patients.
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Figure  5.  hTeRT  mRnA  levels  in  breast  tumor  tissues.  A  real-time 
  qRT-PCR assay was developed on human breast tissues. hTeRT mRnA 
was  normalized  to  beta  actin  mRnA,  and  express  in  relative  unites, 
samples  1–15  were  non-obese  and  16–30  were  obese  by  using  of 
q-gene software.Leptin and hTeRT expression in breast cancer
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in  adipose  tissue  among  obese  women.24  In  obese 
women, the adipose tissue caused secretion of more 
biologically active estrogen to stimulate mammary 
epithelial cell mitosis and development of tumor.25
Recent  studies  have  aimed  to  better  our  under-
standing  of  the  influence  of  adipocyte-derived 
adipocytokines  on  tumorigenesis  in  breast  tissue. 
The discovery of leptin and the demonstration that 
its circulating concentrations in serum positively cor-
relates with BMI, have been followed by attempts to 
link serum leptin levels to breast cancer risk.26 Leptin 
has been implicated as a link between obesity and 
breast cancer.27,28 Some studies show that breast cancer 
patients have higher serum levels of leptin and leptin 
mRNA expression than control subjects, while other 
studies found no correlation in plasma leptin levels 
and breast cancer.29,30 Our study by focusing on the 
mechanism of obesity on hTERT mRNA expression in 
breast tumor tissues indicates that, circulating levels of 
leptin increased in obese breast cancer women and was 
in correlation with hTERT mRNA expression. On the 
other hand, in vitro studies on MCF-7 cell line and 
HepG2 cell line have shown that leptin upregulated the 
expression of hTERT at mRNA and protein levels.31,32 
It showed the mechanism of the proliferative effect of 
leptin on breast cancer cells and provides a new expla-
nation of obesity-related breast cancer.
Recently studies demonstrated that women with 
breast cancer appeared to have high BMI, WC and 
WHR than control subjects, these results suggest that 
general obesity assessed by BMI and central obesity 
measured by WC may both have contributory effects 
on breast cancer risk.33 In the current study, we showed 
positive effects of BMI, WC and WHR on breast can-
cer but the effect WHR was not statistically signifi-
cant. Also, we demonstrated that WC and WHR have 
positive non-significant effects on hTERT expression 
level and hTERT level increased in obese patients, 
especially those with central obesity, it seems leptin 
or some other adipocytokines could be the link. We 
have not found any studies regarding a correlation 
between WC and WHR with hTERT expression.
Some researches deduced the lack of correlation 
between hTERT protein expression and tumor size 
and  grade.34  However,  others  previously  reported 
that  telomerase  activity  correlated  with  these 
clinicopathological parameters.15,16,18 Although it has 
been  shown  hTERT  expression  is  associated  with 
malignancy, it does not seem to correlate with tumor 
stage.17 On the other hand, in high stages a positive 
correlation between hTERT mRNA expression and 
cancer stage has been found in other cancers which 
is  completely  consistent  with  our  present  study.35 
Elkak et al demonstrated that hTERT mRNA expres-
sion is higher, although not statistically significant in 
breast cancer tissues and increased with tumor grade 
progression, which is not completely consistent with 
our study,36 The present study showed high hTERT 
mRNA expression occurred in high grades and stages. 
This could be explained by considering that probably 
high hTERT expression by factors such leptin caused 
tumor  progression  and  affect  clinicopathological 
variables.
In summary, we conclude that high hTERT mRNA 
levels are associated with a poor clinical outcome in 
obese breast cancer patients and could be included 
Table 3. Detection of breast tumor hTeRT mRnA in relation to tumor staging and grading.
Tumor staging Tumor grading
0 I II III IV 0 1 2 3
non-obese cases (%) 6 (17.6) 2 (5.9) 16 (47.1) 9 (26.5) 1 (2.9) 6 (8.6) 12 (17.1) 12 (17.1) 4 (5.7)
Obese cases (%) 1 (2.9) 0 (0) 22 (61.1) 13 (36.1) 0 (0) 1 (1.4) 10 (14.3) 19 (27.1) 6 (8.6)
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as a prognostic marker in future studies. Our study 
revealed a correlation between high serum levels of 
leptin  and  hTERT  expression. These  findings  may 
help to elucidate the mechanisms of hormonal con-
trol of hTERT expression, clarify the key roles of lep-
tin in breast carcinogenesis, and show how obesity 
could increase breast cancer incidence and progres-
sion by leptin production. Meanwhile, in order to best 
understand hormonal control of hTERT expression, 
the correlation between hTERT expression level and 
other adipocytokines must be further studied.
Acknowledgments
This study was financially supported by Cancer Research 
National Network, Tehran, Iran. We are   grateful to all 
individuals who participated in this project.
Disclosure
This  manuscript  has  been  read  and  approved  by 
all authors. This paper is unique and is not under 
consideration by any other publication and has not 
been  published  elsewhere.  The  authors  and  peer 
reviewers of this paper report no conflicts of interest. 
The  authors  confirm  that  they  have  permission  to 
reproduce any copyrighted material.
References
  1.  Smigal C, Jemal A, Ward E, et al. Trends in breast cancer by race and 
  ethnicity: update 2006, CA. Cancer J Clin. 2006;56:168–83.
  2.  Bray F, McCarron P, Parkin D. The changing global patterns of female 
breast cancer incidence and mortality. Breast Cancer Res. 2004;6:229–39.
  3.  Jemal A, Thomas A, Murray T, Thun M. Cancer statistics. CA Cancer J Clin. 
2002;52:23–47.
  4.  Velie EM, Nechuta S, Osuch JR. Lifetime reproductive and anthropometric 
risk factors for breast cancer in ostmenopausal women. Breast Dis. 2005; 
24:17–35.
  5.  Olsson A. Body mass index and breast cancer survival in relation to the 
introduction of mammographic screening. EJSO. 2009;1–7.
  6.  Cleary MP, Maihle NJ. The role of body mass index in the relative risk of 
developing premenopausal versus postmenopausal breast cancer. Proc Soc 
Exp Biol Med. 1997;216:28–43.
  7.  Calle  EE,  Rodriguez  C,  Walker-Thurmond  K,  Thun  MJ.  Overweight, 
  obesity, and mortality from cancer in a prospectively studied cohort of US 
adults. N Engl J Med. 2003;348:1625–38.
  8.  Berclaz  G,  Li  S,  Price  KN,  Coates  AS,  Castiglione-Gertsch  M, 
  Rudenstam CM, et al. Body mass index as a prognostic feature in operable 
breast  cancer:  the  International  Breast  Cancer  Study  Group  experience. 
Ann Oncol. 2004;15:875–84.
  9.  Tworoger SS, Heather Eliassen A, Kelesidis T, Colditz GA, Willett WC, 
Mantzoros CS, et al. Plasma adiponectin concentrations and risk of incident 
breast cancer. J Clin Endocr Metab. 2007;92:1510–6.
  10.  Tian YF, Chu CH, Wu MH, Chang CL, Yang T, Chou YC, et al. Anthropo-
metric measures, plasma adiponectin, and breast cancer risk. Endocr Relat 
Cancer. 2007;14:669–77.
  11.  Meyerson M. Role of telomerase in normal and cancer cells. J Clinical 
Oncology. 2000;13:2626–34.
  12.  Paraskevi K, Sophia P, Stavros H. Structure and function of telomeres/
telomerase and their role in preleukaemia and haematologic malignancies. 
Haema. 2003;6(1):35–47.
  13.  Kumaki F, Kawai T, Hiroi S, Shinomiya N, Ozeki Y, Ferrans VJ, et al. 
Telomerase  activity  and  expression  of  human  telomerase  RNA  compo-
nent and human telomerase reverse transcriptase in lung carcinomas. Hum 
Pathol. 2001;32:188–95.
  14.  Dumont  N,  Crawford  YG,  Sigaroudinia  M,  Nagrani  SS,  Wilson  MB, 
Buehring  GC,  et  al.  Human  mammary  cancer  progression  model  reca-
pitulates methylation events associated with breast premalignancy. Breast 
Cancer Res. 2009;11(6):R87.
  15.  Mokbel  KM,  Parris  CN,  Ghilchik  M,  Amerasinghe  CN,  Newbold  RF. 
Telomerase and lymph vascular invasion in breast cancer. Eur J Surg Oncol. 
2000;126:30–3.
  16.  Mokbel KM, Parris CN, Ghilchik M. The association between telomerase, 
histopathological parameters, and KI-67 expression in breast cancer. Am J 
Surg. 1999;178:69–72.
  17.  Elkak A, Meligonis G, Salhab M, Mitchell B, Blake J, Newbold R, et al. 
hTERT protein expression is independent of clinicopathological parameters 
and c-Myc protein expression in human breast cancer. J Carcinogenesis. 
2005;4:17.
  18.  Zarghami  N,  Mohajeri A,  Rahmati  M.  Prostate  Specific Antigen  Gene 
Expression and Telomerase Activity in Breast Cancer Patients: Possible 
Relationship to Steroid Hormone Receptors. Pharm-Sci. 2007.
  19.  Shay JW. Telomerase and cancer, Molecular Pathology of Early Cancer. 
Edited by Srivastava S, Hensen DE, Gazdar A. Washington, DC. IOS Press. 
1999;405–24.
  20.  World Health Organization Obesity: preventing and managing the global 
epidemic report of a WHO consultation, World Health Organ Tech. Rep Ser. 
2000;89:1–253.
  21.  Yi X, White DM, Aisner DL, Baur JA, Wright W, Shay JW. An alternate 
splicing  variant  of  the  telomerase  catalytic  subunit  inhibits  telomerase 
activity. Neoplasia. 2000;2:433–40.
  22.  Colgin LM, Wilkinson C, Englezou A, Kilian A, Robinson MO, Reddel RR. 
The hTERT a splice variant is a dominant negative inhibitor of telomerase 
activity. Neoplasia. 2000;2:426–32.
  23.  Harvie M, Hooper L, Howell AH. Central obesity and breast cancer risk: 
a systematic review. Obese Rev. 2003;4:157–73.
  24.  Potischman N, Swanson CA, Siiteri P, Hoover RN. Reversal of relation 
between body mass and endogenous estrogen concentrations with meno-
pausal status. Journal of National Cancer Institute. 1996;88:756–8.
  25.  Han DF, Zhou X, Hu MB, Xie W, Mao ZF, Chen DE, et al. Polymorphisms 
of estrogen-metabolizing genes and breast cancer risk: a multigenic study. 
Chin Med J. 2005;118:1507–16.
  26.  Rose DP, Haffner SM, Baillargeon J. Adiposity, the metabolic syndrome, 
and breast cancer in African–American and white American women. Endocr 
Rev. 2007;28:763–77.
  27.  Jarde  T,  Caldefie-Chézet  F,  Goncalves-Mendes  N,  et  al.  Involvement 
of   adiponectin and leptin in breast cancer: clinical and in vitro studies. 
Endocr Relat Cancer. 2009;16:1197–210.
  28.  Roberta F, Mario G, Claudio P, Renato F, Giuseppe P, Laura F, et al. Cellular 
and molecular crosstalk between leptin receptor and estrogen receptor in 
breast cancer: molecular basis for a novel therapeutic setting. Endocr Relat 
Cancer. 2010;17:373–82.
  29.  Stattin P, Soderberg S, Biessy C, Lenner P, Hallmans G, Kaaks R, et al. 
Plasma  leptin  and  breast  cancer  risk:  a  prospective  study  in  northern 
Sweden. Breast Cancer Res Treat. 2004;86:191–6.
  30.  Wang  L,  Lim  E,  Toborek  M,  Hennig  B.  The  role  of  fatty  acids  and 
caveolin-1 in tumor necrosis factor a-inducedvendothelialvcellvactivation. 
Metabolism Clin Exptl. 2008;57:1328–39.
  31.  Ren H, Zhao T, Wang X, et al. Leptin upregulates telomerase activity and 
transcription of human telomerase reverse transcriptase in MCF-7 breast 
cancer cells. Biochem Biophys Res Commun. 2010;394(1):59–63.
  32.  Nikolaos S, Vassilis P, Yoichi F, Yusuke N, Aspasia T. Leptin as a critical 
regulator of hepatocellular carcinoma development through modulation of 
human telomerase reverse transcriptase. BMC Cancer. 2010;10:442.publish with Libertas Academica and 
every scientist working in your field can 
read your article 
“I would like to say that this is the most author-friendly 
editing process I have experienced in over 150 
publications. Thank you most sincerely.”
“The communication between your staff and me has 
been terrific.  Whenever progress is made with the 
manuscript, I receive notice.  Quite honestly, I’ve 
never had such complete communication with a 
journal.”
“LA is different, and hopefully represents a kind of 
scientific publication machinery that removes the 
hurdles from free flow of scientific thought.”
Your paper will be:
•  Available to your entire community 
free of charge
•  Fairly and quickly peer reviewed
•  Yours!  You retain copyright
http://www.la-press.com
Leptin and hTeRT expression in breast cancer
Breast Cancer: Basic and Clinical Research 2011:5  35
  33.  Wu MH, Chou YC, Chou WY, Hsu GC, Chu CH, Yu CP, et al. Circulating 
levels of leptin, adiposity and breast cancer risk. Br J Cancer. 2009;100: 
578–82.
  34.  Kirkpatrick KL, Ogunkolade W, Elkak AE, Bustin S, Jenkins P, Ghilchick M, 
et al. hTERT expression in human breast cancer and non-cancerous breast 
tissue: correlation with tumour stage and c-Myc expression. Breast Cancer 
Res Treat. 2003;77:277–84.
  35.  Li H, Diao TY, Zhou ZY, Yang FY, Ma Q, Li QH. Relationship between 
the expression of hTERT and EYA4 mRNA in peripheral blood mononu-
clear cells with the progressive stages of carcinogenesis of the esophagus. 
J Experimental and Clinical Cancer Research. 2009;28:145.
  36.  Elkak A, Mokbel RC, Wilson C, Jiang W, Newbold R, Mokbel K. hTERT 
mRNA expression is associated with a poor clinical outcome in human 
breast cancer. Anticancer Research. 2006;26:4901–4.